



REC'D 21 FEB 2005

WIPO PCT



PCT/EP2005/000502

19 JAN 2005



INVESTOR IN PEOPLE

EP05/502

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

## PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Andrew Gray*

Dated

29 October 2004

Patents Form 1/77


Patents Act 1977  
(Rule 16)

The  
Patent  
Office

1/77  
Z AN04 866462-000245  
P 1/77 0.00-0 1089.8 COUNT CHA

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office  
Cardiff Road  
Newport  
South Wales NP10 8QQ

1. Your reference

19 JAN 2004

0401089.8

2. Patent application number  
(The Patent Office will fill in this part)

3. Full name, address and postcode of the or  
of each applicant  
(underline all surnames)

NOVARTIS AG  
LICHTSTRASSE 35  
4056 BASEL  
SWITZERLAND

Patent ADP number (if you know it)

If the applicant is a corporate body, give  
the country/state of its incorporation

SWITZERLAND

7125 482005

4. Title of invention

Organic Compounds

5. Name of your agent (If you have one)  
"Address for service" in the United  
Kingdom to which all correspondence  
should be sent  
(including the postcode)

Craig McLean  
Novartis Pharmaceuticals UK Limited  
Patents and Trademarks  
Wimblehurst Road  
Horsham, West Sussex  
RH12 5AB  
07181522002

Patents ADP number (if you know it)

6. If you are declaring priority from one or  
more earlier patent applications, give  
the country and the date of filing of the  
or of each of these earlier applications  
and (if you know it) the or each application  
number

Country

Priority application number  
(if you know it)

Date of filing  
(day/month/year)

7. If this application is divided or otherwise  
derived from an earlier UK  
application, give the number and the  
filing date of the earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of  
right to grant of a patent required in  
support of this request? (Answer 'Yes' if:

No

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- (see note (d))

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 16

Claim(s) 2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



Craig McLean

19<sup>th</sup> January 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. Trevor Drew

(01403) 323069

### Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.


DUPLICATE

- 1 -

Organic Compounds

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.

More particularly the present invention provides a compound of formula I




wherein

R<sub>a</sub> is H; C<sub>1-4</sub>alkyl; or C<sub>1-4</sub>alkyl substituted by OH, NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl or N(di-C<sub>1-4</sub>alkyl)<sub>2</sub>;

R<sub>b</sub> is H; halogen; C<sub>1-4</sub>alkoxy; or C<sub>1-4</sub>alkyl, and

R is a radical of formula (a)



(a)

wherein

R<sub>1</sub> is a heterocyclic residue; or a radical of formula α



wherein X is a direct bond, O, S or NR<sub>11</sub> wherein R<sub>11</sub> is H or C<sub>1-4</sub>alkyl,

R<sub>c</sub> is C<sub>1-4</sub>alkylene or C<sub>1-4</sub>alkylene wherein one CH<sub>2</sub> is replaced by CR<sub>x</sub>R<sub>y</sub> wherein one of R<sub>x</sub> and R<sub>y</sub> is H and the other is CH<sub>3</sub>, each of R<sub>x</sub> and R<sub>y</sub> is CH<sub>3</sub> or R<sub>x</sub> and R<sub>y</sub> form together -CH<sub>2</sub>-CH<sub>2</sub>-,


Y is bound to the terminal carbon atom and is selected from OH, -NR<sub>3</sub>R<sub>4</sub> wherein each of R<sub>3</sub> and R<sub>4</sub>, independently, is H, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl, aryl-C<sub>1-4</sub>alkyl, heteroaryl-C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl or C<sub>1-4</sub>alkyl optionally substituted on the terminal carbon atom by OH, halogen, C<sub>1-4</sub>alkoxy or -NR<sub>5</sub>R<sub>6</sub> wherein each of R<sub>5</sub> and R<sub>6</sub>, independently, is H, C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl, aryl-C<sub>1-4</sub>alkyl, or R<sub>3</sub> and R<sub>4</sub> form together with the nitrogen atom to which they are bound a heterocyclic residue; and

R<sub>2</sub> is H; halogen; C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkoxy; CF<sub>3</sub>; nitrile; nitro or amino.

Any alkyl or alkyl moiety in e.g. alkoxy may be linear or branched. Halogen may be F, Cl, Br or I, preferably F or Cl. Any aryl may be phenyl or naphthyl, preferably phenyl. Heteroaryl may be a 5 to 8 membered aromatic ring comprising 1 to 4 heteroatoms selected from N, O and S, e.g. pyridyl or pyrimidyl.

By heterocyclic residue as  $R_1$  or Y is meant a three to eight, preferably five to eight, membered saturated, unsaturated or aromatic heterocyclic ring comprising 1 or 2 heteroatoms, preferably selected from N, O and S, and optionally substituted; preferably Y comprises a nitrogen as heteroatom and optionally a second heteroatom, preferably selected from N, O and S, and optionally substituted.

Suitable examples for  $R_1$  or Y include e.g. pyridyl, e.g. 3- or 4-pyridyl, piperidyl, e.g. piperidin-1-yl, 3- or 4-piperidyl, homopiperidyl, piperazinyl, homopiperazinyl, imidazolyl, imidazolidinyl, pyrrolyl, pyrrolidinyl or morpholin-4-yl, optionally substituted, e.g. mono- or polysubstituted. When the heterocyclic residue is substituted, this may be on one or more ring carbon atoms and/or on a ring nitrogen atom when present. Examples of a substituent on a ring carbon atom include e.g.  $C_{1-4}$ alkyl e.g.  $CH_3$ ;  $C_{3-6}$ cycloalkyl e.g. cyclopropyl,


optionally further substituted by  $C_{1-4}$ alkyl;  wherein p is 1, 2 or 3, preferably 1;  $CF_3$ ; halogen;  $NH_2$ ;  $-CH_2-NR_7R_8$  wherein each of  $R_7$  and  $R_8$ , independently, is H,  $C_{1-4}$ alkyl, or  $R_7$  and  $R_8$  form together with the nitrogen atom to which they are bound a heterocyclic residue or a heteroaryl;  $-CH_2-OH$ ;  $-CH_2-O-C_{1-4}$ alkyl;  $-CH_2$ -halogen; or  $-CH_2-CH_2$ -halogen. Examples of a substituent on a ring nitrogen atom are e.g.  $C_{1-6}$ alkyl; acyl, e.g.  $R'_x-CO$  wherein  $R'_x$  is H,  $C_{1-6}$ alkyl or phenyl optionally substituted by  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy or amino, e.g. formyl;  $C_{3-6}$ cycloalkyl;  $C_{3-6}$ cycloalkyl- $C_{1-4}$ alkyl; phenyl; phenyl- $C_{1-4}$ alkyl e.g. benzyl; a heterocyclic residue, e.g. as disclosed above, e.g. an aromatic heterocyclic residue comprising 1 or 2 nitrogen atoms; or a residue of formula  $\beta$



wherein  $R_9$  is  $C_{1-4}$ alkylene or  $C_{2-4}$ alkylene interrupted by O and  $Y'$  is OH,  $NH_2$ ,  $NH(C_{1-4}alkyl)$  or  $N(C_{1-4}alkyl)_2$ .  $C_{2-4}$ alkylene interrupted by O may be e.g.  $-CH_2-CH_2-O-CH_2-CH_2-$ .

When the substituent on a cyclic nitrogen is a heterocyclic residue, it may be a five or six membered saturated, unsaturated or aromatic heterocyclic ring comprising 1 or 2 heteroatoms, preferably selected from N, O and S. Examples include e.g. 3- or 4-pyridyl, piperidyl, e.g. piperidin-1-yl, 3- or 4-piperidyl, homopiperidyl, piperazinyl, homopiperazinyl, pyrimidinyl, morpholin-4-yl, imidazolyl, imidazolidinyl, pyrrolyl or pyrrolidinyl.

Further examples of heterocyclic residue as  $R_1$  or  $Y$  include e.g. a residue of formula ( $\gamma$ )



wherein

the ring D is a 5, 6 or 7 membered saturated, unsaturated or aromatic ring;

$X_b$  is  $-N=$ ,  $-C=$  or  $-CH-$ ;

$X_c$  is  $-N=$ ,  $-NR_1$ ,  $-CR_1'$  or  $-CHR_1'$  wherein  $R_1$  is a substituent as indicated above for a ring nitrogen atom, and  $R_1'$  is a substituent as indicated above for a ring carbon atom;

the bond between  $C_1$  and  $C_2$  is either saturated or unsaturated;

each of  $C_1$  and  $C_2$ , independently, is a carbon atom which is optionally substituted by one or two substituents selected among those indicated above for a ring carbon atom; and

the line between  $C_3$  and  $X_b$  and between  $C_1$  and  $X_b$ , respectively, represents the number of carbon atoms as required to obtain a 5, 6 or 7 membered ring D,

whereby when  $Y$  is a residue of formula ( $\gamma$ ) at least one of  $X_b$  and  $X_c$  is  $-N=$ .

A preferred residue of formula ( $\gamma$ ) is one wherein the ring D forms a 1,4-piperazinyl ring optionally C- and/or N-substituted as indicated.

Representative examples of a residue of formula ( $\gamma$ ) are e.g. 3- or 4- pyridyl; piperidin-1-yl; 1-N-( $C_{1-4}$ alkyl)- or  $-(\omega$ -hydroxy- $C_{1-4}$ alkyl)-3-piperidyl; morpholin-4-yl; imidazolyl; pyrrolidinyl; 1-piperazinyl; 2- $C_{1-4}$ alkyl- or  $-C_{3-6}$ cycloalkyl-1-piperazinyl ; 3- $C_{1-4}$ alkyl- or  $-C_{3-6}$ cycloalkyl-1-piperazinyl; 2,2- or 3,5- or 2,5- or 2,6-di( $C_{1-4}$ alkyl)-1-piperazinyl; 3,4,5-tri-( $C_{1-4}$ alkyl)-1-piperazinyl; 4-N-( $C_{1-4}$ alkyl)- or  $-(\omega$ -hydroxy- $C_{1-4}$ alkyl)- or  $-(\omega$ -dimethylamino- $C_{1-4}$ alkyl)-1-piperazinyl; 4-N-pyridin-4-yl-1-piperazinyl; 4-N-phenyl- or  $-C_{3-6}$ cycloalkyl-1-piperazinyl; 4-N-( $C_{1-4}$ alkyl)- or  $-(\omega$ -hydroxy- $C_{1-4}$ alkyl)-3- $C_{1-4}$ alkyl- or -3,3-di( $C_{1-4}$ alkyl)-1-piperazinyl; 4-N-(1- $C_{1-4}$ alkyl- $C_{3-6}$ cycloalkyl)-1-piperazinyl; 4-N-formyl-1-piperazinyl; 4-N-pyrimidin-2-yl-1-piperazinyl; or 4-N- $C_{1-4}$ alkyl-1-homopiperazinyl.

When  $R_a$  is substituted  $C_{1-4}$ alkyl, the substituent is preferably on the terminal carbon atom.


The compounds of formula I may exist in free form or in salt form, e.g. addition salts with e.g. organic or inorganic acids, for example, hydrochloric acid, acetic acid, trifluoroacetic acid.

It will be appreciated that the compounds of formula I may exist in the form of optical isomers, racemates or diastereoisomers. For example, a ring carbon atom bearing a substituent in the position 3 of the piperazinyl residue is asymmetric and may have the R- or S- configuration. It is to be understood that the present invention embraces all enantiomers and their mixtures. Enantiomers are preferred over racemates. Similar considerations apply in relation to starting materials exhibiting asymmetric carbon atoms as mentioned.


In the compounds of formula I, the following significances are preferred individually or in any sub-combination:

1.  $R_a$  is H or methyl;
2.  $R_b$  is H, methyl or ethyl;
3.  $R_1$  is a heterocyclic residue, preferably  $R_1$  is piperazin-1-yl optionally substituted by  $CH_3$  in position 3 and/or 4 or in position 3 by ethyl;  $-CH_2NR_7R_8$ ,  $C_{1-4}$ alkoxy- $C_{1-4}$ alkyl or halogeno- $C_{1-4}$ alkyl; even more preferably piperazin-1-yl substituted by  $CH_3$  in position 4;
4.  $R_2$  is H; Cl or  $CF_3$ .

The present invention also includes a process for the preparation of a compound of formula I which process comprises reacting a compound of formula II



wherein  $R_a$  and  $R_b$  are as defined above,  
with a compound of formula III



wherein R is as defined above,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

The process may conveniently be effected in the presence of a strong base, e.g. t-BuOK, e.g. as disclosed in WO02/38561 or WO 03/08259, the contents of which being incorporated herein by reference, and as illustrated in the Examples.


Compounds of formula II and III may be prepared in accordance with known methods, e.g. as disclosed in WO02/38561 or WO 03/08259, the contents of which being incorporated herein by reference, and as illustrated in the Examples.

Insofar as the production of the starting materials is not particularly described, the compounds are known or may be prepared analogously to methods known in the art or as described hereafter.

The following examples are illustrative of the invention without any limitation.

RT	=	room temperature
THF	=	tetrahydrofuran
DMF	=	dimethylformamide
EtOAc	=	ethylacetate
$\text{Pd}_2(\text{dba})_3$	=	$\text{Pd}(0)$ -bis(dibenzylidenacetone)
FCC	=	flash column chromatography
TLC	=	thin layer chromatography

**Example 1:** 3-(7-Methyl-1H-indol-3-yl)-4-[5-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-pyrrole-2,5-dione



2-[5-(4-Methyl-piperazin-1-yl)-pyridin-3-yl]-acetamide (150 mg, 0.64 mmol) and (7-methyl-1H-indol-3-yl)-oxo-acetic acid methyl ester (209 mg, 0.96 mmol) were dissolved under an atmosphere of argon in a mixture of dry DMF (2 ml) and dry THF (2 ml). A solution of 1.0 M KOtBu in THF (1.9 ml, 1.9 mmol) was then added at RT. After 1 h at 50 °C, TLC analysis indicated complete conversion of starting materials. The reaction mixture was diluted with EtOAc and poured into a saturated aqueous  $\text{NH}_4\text{Cl}$  solution. The organic layer was separated, washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and the organic solvent was evaporated. The residue was purified by FCC (EtOAc / AcOH /  $\text{H}_2\text{O}$  600 : 115 : 150) to afford the title compound.  $^1\text{H}$  NMR ( $\text{d}_6$ -DMSO 400 MHz):  $\delta$  2.15 (s, 3H), 2.28 – 2.32 (m, 2H), 2.92 – 3.00 (m, 2H), 3.15 (s, 3H), 6.21 (d,  $J$  = 9 Hz, 1H), 6.64 (t,  $J$  = 9 Hz, 1H), 6.88 (d,  $J$  = 9 Hz, 1H), 7.22 (s, 1H), 7.98 (br s, 1H), 8.20 – 8.22 (m, 1H).  $\text{ES}^+$ -MS: 402.6  $[\text{M} + \text{H}]^+$ .



*Preparation of 2-[5-(4-Methyl-piperazin-1-yl)-pyridin-3-yl]-acetamide*

[5-(4-Methyl-piperazin-1-yl)-pyridin-3-yl]-acetic acid (1.57 g, 5.78 mmol) and carbonyl diimidazole (1.03 g, 6.36 mmol) were dissolved under an atmosphere of argon in DMF (16 ml). After stirring at RT for 1 h, aqueous  $\text{NH}_4\text{OH}$  (25%, 16 ml) was added, and stirring at RT was continued for 15 minutes. TLC analysis indicated complete consumption of starting material. The aqueous layer was saturated with NaCl and extracted repeatedly with  $\text{CH}_2\text{Cl}_2$ . The organic layers were dried over  $\text{Na}_2\text{SO}_4$  and concentrated. Purification by FCC ( $\text{CH}_2\text{Cl}_2$  : MeOH 95 : 5 to 90 : 10 to 80 : 20 to 70 : 30 to 50 : 50 to 25 : 75 to 0 : 100) yielded the title compound.  $^1\text{H}$  NMR ( $d_6$ -DMSO 400 MHz):  $\delta$  2.76 (s, 3H), 3.12 – 3.42 (m, 8H), 3.34 (s, 2H), 6.86 – 6.96 (br s, 1H), 7.26 (s, 1H), 7.93 (s, 1H), 8.21 (s, 1H).  $\text{ES}^+$ -MS: 235.4  $[\text{M} + \text{H}]^+$ .

*Preparation of [5-(4-Methyl-piperazin-1-yl)-pyridin-3-yl]-acetic acid*

[5-(4-Methyl-piperazin-1-yl)-pyridin-3-yl]-acetic acid tert-butyl ester (1.68 g, 5.77 mmol) was dissolved in 4 M HCl in dioxane (28 ml). After 1 h at 60 °C, TLC analysis indicated complete consumption of starting material. The reaction mixture was cooled to RT and diluted with  $\text{Et}_2\text{O}$ . The precipitate was filtered and washed with  $\text{Et}_2\text{O}$  to yield the title compound, which was used in the next reaction without further purification.  $^1\text{H}$  NMR ( $d_6$ -DMSO 400 MHz):  $\delta$  2.79 (s, 3H), 3.05 – 4.10 (br m, 8 H), 3.81 (s, 2H), 8.04 (s, 1H), 8.22 (s, 1H), 8.45 (s, 1H).  $\text{ES}^+$ -MS: 236.4  $[\text{M} + \text{H}]^+$ .

*Preparation of 2-[5-(4-Methyl-piperazin-1-yl)-pyridin-3-yl]-acetamide [5-(4-Methyl-piperazin-1-yl)-pyridin-3-yl]-acetic acid tert-butyl ester*

Potassium phosphate (4.08 g, 19.21 mmol) was dried under high vacuum at 100 °C for 90 minutes. After cooling to RT and venting with argon,  $\text{Pd}_2(\text{dba})_3$  (70 mg, 0.077 mmol), dicyclohexyl-(2',4',6'-triisopropyl-biphenyl-2-yl)-phosphane (183 mg, 0.38 mmol), a degassed mixture of toluene / tert-butanol (9 : 1, 20 ml) and N-methyl piperazine (1.15 g, 11.53 mmol) were added. The reaction mixture was immersed in a pre-heated oil bath (100 °C). After 2 h at 100 °C, additional  $\text{Pd}_2(\text{dba})_3$  (70 mg, 0.077 mmol) and dicyclohexyl-(2',4',6'-triisopropyl-biphenyl-2-yl)-phosphane (183 mg, 0.38 mmol) were added. After an additional 2 h at 100 °C, TLC analysis indicated complete conversion of starting material. The reaction mixture was cooled to RT, diluted with water and extracted with  $\text{CH}_2\text{Cl}_2$ . The combined organic layers were dried over  $\text{Na}_2\text{SO}_4$  and concentrated. Purification by FCC ( $\text{CH}_2\text{Cl}_2$  : MeOH 95 : 5 to 92 : 8 to 88 : 12 to 80 : 20) yielded the title compound.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.57 (s, 9H),

2.48 (s, 3H), 2.68 – 2.72 (m, 4H), 3.35 – 3.40 (m, 4H), 3.60 (s, 2H), 7.24 – 7.27 (m, 1H), 8.10 (br s, 1H), 8.32 – 8.33 (m, 1H). ES<sup>+</sup>-MS: 292.4 [M + H]<sup>+</sup>.


*Preparation of (5-Chloro-pyridin-3-yl)-acetic acid tert-butyl ester*

Pd<sub>2</sub>(dba)<sub>3</sub> (928 mg, 1.01 mmol) and (2'-dicyclohexylphosphanyl-biphenyl-2-yl)-dimethylamine (838 mg, 2.13 mmol) were added at RT under an atmosphere of argon to a solution of lithium hexamethyl disilazide in toluene (prepared by addition of n-BuLi (1.6 M in hexane, 24.3 ml, 38.85 mmol) to hexamethyl disilazane (6.27 g, 38.85 mmol) in toluene (100 ml) at -78 °C). The mixture was stirred at RT for 10 minutes, then it was cooled to -10 °C. Acetic acid tert-butyl ester (4.12 g, 35.48 mmol) was added during 10 minutes. This mixture was cannulated into a cold (-10 °C) solution of 1,3-dichloropyridine (5.00 g, 33.79 mmol) in toluene (40 ml). The mixture was warmed to RT and stirred for 2 h. TLC analysis indicated substantial conversion of starting material. Water was added, the resulting slurry was filtered, and the filtrate was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. Purification by FCC (hexane / EtOAc 100 : 0 to 92 : 8 to 85 : 15) yielded the title compound. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.39 (s, 9H), 3.47 (s, 2H), 7.58 – 7.60 (m, 1H), 8.31 (s, 1H), 8.41 – 8.42 (m, 1H). ES<sup>+</sup>-MS: 228.3 [M + H]<sup>+</sup>.

By following the procedure of Example 1, but using the appropriate starting materials, the compounds of formula A wherein R<sub>a</sub>, R<sub>b</sub>, and R<sub>3</sub> are as indicated in Table 1 below, may be obtained.

Table 1

	R <sub>3</sub>	R <sub>a</sub>	R <sub>b</sub>	MS
2.	Cl	H	CH <sub>3</sub>	MH <sup>+</sup> 436
3.	H	CH <sub>3</sub>	H	MH <sup>+</sup> 402
4.	H	H	H	MH <sup>+</sup> 388
5.	CF <sub>3</sub>	H	CH <sub>3</sub>	MH <sup>+</sup> 470
6.	CF <sub>3</sub>	H	H	MH <sup>+</sup> 456
7.	CF <sub>3</sub>	CH <sub>3</sub>	H	MH <sup>+</sup> 470



A

The compounds of formula I in free form or in pharmaceutically acceptable salt form exhibit valuable pharmacological properties, e.g. inhibiting Protein Kinase C (PKC), e.g. PKC isoforms like  $\alpha$ ,  $\beta$ ,  $\delta$ ,  $\epsilon$ ,  $\eta$  or  $\theta$  activity, inhibiting T-cell activation and proliferation, e.g. by inhibiting production by T-cells or cytokines, e.g. IL-2, by inhibiting the proliferative response of T-cells to cytokines, e.g. IL-2, e.g. as indicated in in vitro and in vivo tests and are therefore indicated for therapy.

#### A. In vitro

##### 1. Protein Kinase C assay

The compounds of formula I are tested for their activity on different PKC isoforms according to a published method (D. Geiges et al. Biochem. Pharmacol. 1997;53:865-875). The assay is performed in a 96-well polypropylene microtiterplate (Costar 3794) that has been previously siliconized with Sigmacote (Sigma SL-2). The reaction mixture (50  $\mu$ l) contains 10  $\mu$ l of the relevant PKC isozyme together with 25  $\mu$ l of the test compound and 15  $\mu$ l of a mix solution that contains 200  $\mu$ g/ml protamine sulfate, 10 mM Mg(NO<sub>3</sub>)<sub>2</sub>, 10  $\mu$ M ATP (Boehringer 519987) and 3750 Bq of <sup>33</sup>P-ATP (Hartmann Analytic SFC301, 110TBq/mmol) in 20 mM Tris-buffer pH 7.4 + 0.1% BSA. Incubation is performed for 15 min at 32°C in a microtiterplate shaking incubator (Biolabo Scientific Instruments). Reaction is stopped by adding 10  $\mu$ l of 0.5 M Na<sub>2</sub>EDTA, pH 7.4. 50  $\mu$ l of mixture are pipetted onto a pre-wetted phosphocellulose paper (Whatmann 3698-915) under gentle pressure. Non-incorporated ATP is washed away with 100  $\mu$ l bi-dist H<sub>2</sub>O. The paper is washed twice in 0.5% H<sub>3</sub>PO<sub>4</sub> for 15 min followed by 5 min in EtOH. Thereafter the paper is dried and placed in an omnifilter (Packard 6005219), and overlayed with 10  $\mu$ l/well of Microscint-O (Packard 6013611) before counting in a Topcount radioactivity counter (Packard). IC<sub>50</sub> measurement is performed on a routine basis by incubating a serial dilution of inhibitor at concentrations ranging between 1-

1000  $\mu$ M according to the method described above.  $IC_{50}$  value are calculated from the graph by sigmoidal curve fitting.

2. Protein Kinase C  $\theta$  Assay

Human recombinant PKC $\theta$  is used under the assay conditions as described above. In this assay, compounds of formula I inhibit PKC  $\theta$  with an  $IC_{50} \leq 1 \mu$ M.

3. Protein Kinase C $\alpha$  Assay

Human recombinant PKC $\alpha$  was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC $\alpha$  with an  $IC_{50} \leq 1 \mu$ M.

4. Protein Kinase C $\beta$ 1 Assay

Human recombinant PKC $\beta$ 1 was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC $\beta$ 1 with an  $IC_{50} \leq 1 \mu$ M.

5. Protein Kinase C $\delta$  Assay

Human recombinant PKC $\delta$  was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC $\delta$  with an  $IC_{50} \leq 1 \mu$ M.

6. Protein Kinase C $\epsilon$  Assay

Human recombinant PKC $\epsilon$  was obtained from Oxford Biomedical Research and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC $\epsilon$  with an  $IC_{50} \leq 1 \mu$ M.

7. Protein Kinase C $\eta$  Assay

Human recombinant PKC $\eta$  was obtained from PanVera and is used under the assay conditions as described under Section A.1 above. In this assay, compounds of formula I inhibit PKC $\eta$  with an  $IC_{50} \leq 1 \mu$ M.

8. CD28 costimulation assay

The assay is performed with Jurkat cells transfected with a human interleukin-2 promoter/reporter gene construct as described by Baumann G et al. in Transplant. Proc. 1992;24:43-8, the  $\beta$ -galactosidase reporter gene being replaced by the luciferase gene (de Wet J., et al., Mol. Cell Biol. 1987, 7(2), 725-737). Cells are stimulated by solid phase-coupled antibodies or phorbol myristate acetate (PMA) and the  $Ca^{++}$  ionophore ionomycin as

follows. For antibody-mediated stimulation Microlite TM1 microtiter plates (Dynatech) are coated with 3 µg/ml goat anti-mouse IgG Fc antibodies (Jackson) in 55 µl phosphate-buffered saline (PBS) per well for three hours at RT. Plates are blocked after removing the antibodies by incubation with 2% bovine serum albumin (BSA) in PBS (300 µl per well) for 2 hours at RT. After washing three times with 300 µl PBS per well, 10 ng/ml anti-T cell receptor antibodies (WT31, Becton & Dickinson) and 300 ng/ml anti-CD28 antibodies (15E8) in 50 µl 2% BSA/PBS are added as stimulating antibodies and incubated overnight at 4°C. Finally the plates are washed three times with 300 µl PBS per well. Seven three-fold serial dilutions of test compounds in duplicates in assay medium (RPMI 1640/10% fetal calf serum (FCS) containing 50 µM 2-mercaptoethanol, 100 units/ml penicillin and 100 µg/ml streptomycin) are prepared in separate plates, mixed with transfected Jurkat cells (clone K22 290\_H23) and incubated for 30 minutes at 37°C in 5% CO<sub>2</sub>. 100 µl of this mixture containing  $1 \times 10^5$  cells are then transferred to the antibody-coated assay plates. In parallel 100 µl are incubated with 40 ng/ml PMA and 2 µM ionomycin. After incubation for 5.5 hours at 37°C in 5% CO<sub>2</sub>, the level of luciferase is determined by bioluminescence measurement. The plates are centrifuged for 10 min at 500 g and the supernatant is removed by flicking. Lysis buffer containing 25 mM Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10 % (v/v) glycerol and 1 % (v/v) Triton X-100 is added (20 µl per well). The plates are incubated at RT for 10 minutes under constant shaking. Luciferase activity is assessed with a bioluminescence reader (Labsystem, Helsinki, Finland) after automatic addition of 50 µl per well luciferase reaction buffer containing 20 mM Tricine, 1.07 mM (MgCO<sub>3</sub>)<sub>4</sub>Mg(OH)<sub>2</sub>·5H<sub>2</sub>O, 2.67 mM MgSO<sub>4</sub>, 0.1 mM EDTA, 33.3 mM DTT, 270 µM coenzyme A, 470 µM luciferin (Chemie Brunschwig AG), 530 µM ATP, pH 7.8. Lag time is 0.5 seconds, total measuring time is 1 or 2 seconds. Low control values are light units from anti-T cell receptor- or PMA-stimulated cells, high controls are from anti-T cell receptor/anti-CD28- or PMA/ionomycin-stimulated cells without any test sample. Low controls are subtracted from all values. The inhibition obtained in the presence of a test compound is calculated as percent inhibition of the high control. The concentration of test compounds resulting in 50% inhibition (IC<sub>50</sub>) is determined from the dose-response curves. In this assay, compounds of formula I inhibit anti-T cell receptor/anti-CD28 and PMA/ionomycin stimulated Jurkat cells with an IC<sub>50</sub> ≤ 1 µM.

9. Allogeneic Mixed Lymphocyte Reaction (MLR)

The two-way MLR is performed according to standard procedures (J. Immunol. Methods, 1973, 2, 279 and Meo T. et al., Immunological Methods, New York, Academic Press, 1979, 227-39). Briefly, spleen cells from CBA and BALB/c mice ( $1.6 \times 10^5$  cells from each strain per well in flat bottom tissue culture microtiter plates,  $3.2 \times 10^5$  in total) are incubated in RPMI medium containing 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco BRL, Basel, Switzerland), 50 µM 2-mercaptoethanol (Fluka, Buchs, Switzerland) and serially diluted compounds. Seven three-fold dilution steps in duplicates per test compound are performed. After four days of incubation 1 µCi  $^3\text{H}$ -thymidine is added. Cells are harvested after an additional five-hour incubation period, and incorporated  $^3\text{H}$ -thymidine is determined according to standard procedures. Background values (low control) of the MLR are the proliferation of BALB/c cells alone. Low controls are subtracted from all values. High controls without any sample are taken as 100% proliferation. Percent inhibition by the samples is calculated, and the concentrations required for 50% inhibition ( $\text{IC}_{50}$  values) are determined.

#### 10. Inhibition of GSK-3β

The GSK-3β bidding assay is performed in 50µl reactions in 96 well polypropylene plate, each reaction containing 20mM magnesium chloride, 40 µM ATP, 2mM DTT, 88.5µM biotinylated and phosphorylated CREB-peptide substrate (biotin-KRREILSRPS( $\text{PO}_4$ )YR-OH ; Q. M. Wang et al., J. Biol. Chem. 269, 14566-14574, 1994), [ $\gamma$ - $^{33}\text{P}$ ]ATP (1µCi) and 2µl of the compound to be tested in DMSO(various concentrations). 15µl of GSK-3β (various concentrations) is added and the mixture is incubated at 30°C for 1 hour. The reaction is stopped by transferring 25 µl of the mixture to a phosphocellulose plate containing 130µl of 1.85% phosphoric acid. The free radionucleotides in the membrane are washed off under vacuum with 1.85% phosphoric acid (5 times). After the last wash, the plate is transferred to an adaptor plate and 50µl of scintillation cocktail (Microscint-20, Packard, cat. # 20-133) is added to each well and the amount of radioactivity is counted in a top counter. Compounds of formula I are active in this assay.

#### B. In vivo

##### Rat Heart transplantation

The strain combination used: Male Lewis ( $\text{RT}^1$  haplotype) and BN ( $\text{RT}^1$  haplotype). The animals are anaesthetised using inhalational isoflurane. Following heparinisation of the donor rat through the abdominal inferior vena cava with simultaneous exsanguination via the aorta, the chest is opened and the heart rapidly cooled. The aorta is ligated and divided distal to the first branch and the brachiocephalic trunk is divided at the first bifurcation. The

left pulmonary artery is ligated and divided and the right side divided but left open. All other vessels are dissected free, ligated and divided and the donor heart is removed into iced saline.

The recipient is prepared by dissection and cross-clamping of the infra-renal abdominal aorta and vena cava. The graft is implanted with end-to-side anastomoses, using 10/0 monofilament suture, between the donor brachiocephalic trunk and the recipient aorta and the donor right pulmonary artery to the recipient vena cava. The clamps are removed, the graft tethered retroabdominally, the abdominal contents washed with warm saline and the animal is closed and allowed to recover under a heating lamp. Graft survival is monitored by daily palpation of the beating donor heart through the abdominal wall. Rejection is considered to be complete when heart beat stops. Increases of graft survival are obtained in animals treated with a compound of formula I administered orally at a daily dose of 1 to 30 mg/kg bid.

#### Graft v. Host Model

Spleen cells ( $2 \times 10^7$ ) from Wistar/F rats are injected subcutaneously into the right hind footpad of (Wistar/F x Fischer 344) $F_1$  hybrid rats. The left footpad is left untreated. The animals are treated with the test compounds on 4 consecutive days (0-3). The popliteal lymph nodes are removed on day 7, and the weight differences between two corresponding lymph nodes are determined. The results are expressed as the inhibition of lymph node enlargement (given in percent) comparing the lymph node weight differences in the experimental groups to the weight difference between the corresponding lymph nodes from a group of animals left untreated with a test compound.

The compounds of formula I are, therefore, useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of formula I are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g.

rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrheic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis. For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.1 to about 100 mg/kg body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 2000 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form.

The compounds of formula I may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, or parenterally, e.g. in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Pharmaceutical compositions comprising a compound of formula I in free form or in pharmaceutically acceptable salt form in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance.

Topical administration is e.g. to the skin. A further form of topical administration is to the eye.

The compounds of formula I may be administered in free form or in pharmaceutically acceptable salt form e.g. as indicated above. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.

In accordance with the foregoing the present invention further provides:

- 1.1 A method for preventing or treating disorders or diseases mediated by T lymphocytes and/or PKC or GSK-3 $\beta$ , e.g. such as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;



- 1.2 A method for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, e.g. as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;
2. A compound of formula I, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical, e.g. in any of the methods as indicated under 1.1 and 1.2 above.
3. A pharmaceutical composition, e.g. for use in any of the methods as in 1.1 and 1.2 above comprising a compound of formula I in free form or pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.
4. A compound of formula I or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition for use in any of the method as in 1.1 and 1.2 above.

Compounds of formula I may be administered as the sole active ingredient or together with other drugs in immunomodulating regimens or other anti-inflammatory agents e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders. For example, they may be used in combination with cyclosporines, or ascomycines or their immunosuppressive analogs or derivatives, e.g. cyclosporin A, ISA Tx247, FK-506, ABT-281, ASM 981; an mTOR inhibitor, e.g. rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, or a rapalog, e.g. AP23573, AP23464, AP23675, AP23841, TAFA-93, biolimus 7 or biolimus 9 etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; an EDG receptor agonist having accelerating lymphocyte homing properties, e.g. FTY 720 or an analogue thereof; leflunomide or analogs thereof; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine or analogs thereof; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD 11a/CD18, CD7, CD25, CD 27, B7, CD40, CD45, CD58, CD 137, ICOS, CD150 (SLAM), OX40, 4-1BB or their ligands, e.g. CD154; or other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant

thereof, e.g. LEA29Y, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including LFA-1 antagonists, Selectin antagonists and VLA-4 antagonists. Compounds of formula I may also be administered together with an antiproliferative drug, e.g. a chemotherapeutic drug, e.g. as used in cancer treatment, including but not limited to aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bengamides, bisphosphonates, antiproliferative antibodies and temozolomide, or with an anti-diabetic drug, an insulin secretagogue or insulin secretion enhancer, e.g. a sulphonyl urea, e.g. tolbutamide, chlorpropamide, tolazamide, acetohexamide, 4-chloro-N-[(1-pyrrolidinyl-amino)carbonyl]-benzensulfonamide (glycopyramide), glibenclamide (glyburide), glliclazide, 1-butyl-3-metanilylurea, carbutamide, glibonuride, glipizide, gliquidone, glioxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide or tolycyclamide, an oral insulinotropic agent derivative, e.g. a short acting insulin enhancer, e.g. meglitinide, repaglinide, a phenyl acetic acid derivative, e.g. nateglinide, a DPP IV inhibitor, e.g. 1-{2-[(5-cyanopyridin-2-yl)amino]ethylamino}acetyl-(2S)-cyano-pyrrolidine dihydrochloride, LAF237, GLP-1 or a GLP-1 agonist analog, or an insulin sensitizer e.g. a peroxisome proliferator activated receptor  $\gamma$  agonist (PPAR $\gamma$ ), e.g. a glitazone, a non-glitazone type such as a N-(2-benzoylphenyl)-L-tyrosine analogue, e.g. GI-262570, or an oxolidinedione, e.g. JTT501, a dual PPAR $\gamma$ /PPAR $\alpha$  agonist, e.g. DRF-554158, NC-2100 or NN-622, a retinoid X receptor agonist or a rexinoid, e.g. 2-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-cyclopropyl]-pyridine-5-carboxylic acid, 4-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-carbonyl]-benzoic acid, 9-cis retinoic acid or an analog, derivative or a pharmaceutically acceptable salt thereof, in diabetes therapy.

In accordance with the foregoing the present invention provides in a yet further aspect:

5. A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of an inhibitor of GSK-3 $\beta$ , PKC or of T-cell activation and proliferation, e.g. a compound of formula I in free form or in pharmaceutically acceptable salt form, and a second drug substance, said second drug substance being an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug, e.g. as indicated above.


6. A therapeutic combination, e.g. a kit, comprising a) an inhibitor of GSK-3 $\beta$ , PKC or of T-cell activation and proliferation, e.g. a compound of formula I in free form or in pharmaceutically acceptable salt form, and b) at least one second agent selected from an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative and anti-diabetic drug. Component a) and component b) may be used concomitantly or in sequence. The kit may comprise instructions for its administration.

Where an inhibitor of GSK-3 $\beta$ , PKC or of T-cell activation and proliferation, e.g. a compound of formula I, is administered in conjunction with other immunosuppressive/immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic therapy, e.g. for preventing or treating acute or chronic graft rejection or inflammatory or autoimmune disorders as hereinabove specified, dosages of the co-administered immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a cyclosporine, on the specific drug employed, on the condition being treated and so forth.

Compounds of formula I have an interesting pharmacokinetic profile and interesting in vitro and in vivo activities.

## CLAIMS

1. A compound of formula I




wherein

$R_a$  is H;  $C_{1-4}$ alkyl; or  $C_{1-4}$ alkyl substituted by OH,  $NH_2$ ,  $NHC_{1-4}$ alkyl or  $N(di-C_{1-4}alkyl)_2$ ;

$R_b$  is H; halogen;  $C_{1-6}$ alkoxy; or  $C_{1-6}$ alkyl, and

R is a radical of formula (a)



wherein

$R_1$  is a heterocyclic residue; or a radical of formula  $\alpha$



wherein X is a direct bond, O, S or  $NR_{11}$  wherein  $R_{11}$  is H or  $C_{1-4}$ alkyl,

$R_c$  is  $C_{1-4}$ alkylene or  $C_{1-4}$ alkylene wherein one  $CH_2$  is replaced by  $CR_xR_y$  wherein one of  $R_x$  and  $R_y$  is H and the other is  $CH_3$ , each of  $R_x$  and  $R_y$  is  $CH_3$  or  $R_x$  and  $R_y$  form together  $-CH_2-CH_2-$ ,

Y is bound to the terminal carbon atom and is selected from OH,  $-NR_3R_4$  wherein each of  $R_3$  and  $R_4$ , independently, is H,  $C_{3-6}$ cycloalkyl,  $C_{3-6}$ cycloalkyl- $C_{1-4}$ alkyl, aryl- $C_{1-4}$ alkyl, heteroaryl- $C_{1-4}$ alkyl,  $C_{2-6}$ alkenyl or  $C_{1-4}$ alkyl optionally substituted on the terminal carbon atom by OH, halogen,  $C_{1-4}$ alkoxy or  $-NR_5R_6$  wherein each of  $R_5$  and  $R_6$ , independently, is H,  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{3-6}$ cycloalkyl- $C_{1-4}$ alkyl, aryl- $C_{1-4}$ alkyl, or  $R_3$  and  $R_4$  form together with the nitrogen atom to which they are bound a heterocyclic residue; and  $R_2$  is H; halogen;  $C_{1-4}$ alkyl;  $C_{1-4}$ alkoxy;  $CF_3$ ; nitrile; nitro or amino; or a salt thereof,

a process for its preparation, its use as a pharmaceutical, a pharmaceutical composition containing such a compound or a pharmaceutically acceptable salt thereof, a method of treatment or prevention using such a compound or a

pharmaceutically acceptable salt thereof, or a pharmaceutical combination comprising such a compound or a pharmaceutically acceptable salt thereof, substantially as herein defined and/or described.

2. A compound substantially as described in the Examples.